Viatris Inc
NASDAQ:VTRS

Watchlist Manager
Viatris Inc Logo
Viatris Inc
NASDAQ:VTRS
Watchlist
Price: 11.955 USD 0.13%
Market Cap: 13.8B USD

Relative Value

The Relative Value of one VTRS stock under the Base Case scenario is 27.417 USD. Compared to the current market price of 11.955 USD, Viatris Inc is Undervalued by 56%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VTRS Relative Value
Base Case
27.417 USD
Undervaluation 56%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
9
vs Industry
76
Median 3Y
0.8
Median 5Y
0.8
Industry
2.6
Forward
1
vs History
vs Industry
1
Median 3Y
-2.7
Median 5Y
-3.2
Industry
21.6
Forward
5.1
vs History
14
vs Industry
48
Median 3Y
4.7
Median 5Y
4.8
Industry
16.5
vs History
9
vs Industry
29
Median 3Y
-5.3
Median 5Y
10
Industry
22.5
vs History
0
vs Industry
72
Median 3Y
0.6
Median 5Y
0.6
Industry
2.3
vs History
38
vs Industry
56
Median 3Y
1.8
Median 5Y
1.8
Industry
2.9
Forward
1.7
vs History
23
vs Industry
50
Median 3Y
4.1
Median 5Y
4.2
Industry
5.5
vs History
30
vs Industry
45
Median 3Y
5.4
Median 5Y
5.4
Industry
13
Forward
6
vs History
23
vs Industry
26
Median 3Y
15.5
Median 5Y
15.9
Industry
16.6
Forward
6.6
vs History
19
vs Industry
37
Median 3Y
11
Median 5Y
11
Industry
15.8
vs History
19
vs Industry
29
Median 3Y
13.3
Median 5Y
13.4
Industry
19.1
vs History
0
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9

Multiples Across Competitors

VTRS Competitors Multiples
Viatris Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Viatris Inc
NASDAQ:VTRS
13.8B USD 1 -3.8 6.1 19.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.9 36.8 39.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
500.1B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
257.6B CHF 4.2 27.3 11.7 13.6
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP 4.8 30 108.3 158.5
CH
Novartis AG
SIX:NOVN
206.1B CHF 4.6 18 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
249.9B USD 3.9 13.2 9.4 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.3B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
Viatris Inc
NASDAQ:VTRS
Average P/E: 23.9
Negative Multiple: -3.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Viatris Inc
NASDAQ:VTRS
Average EV/EBITDA: 399.5
6.1
-1%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Viatris Inc
NASDAQ:VTRS
Average EV/EBIT: 1 711.9
19.1
32%
0.6
US
Eli Lilly and Co
NYSE:LLY
39.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3